Market Overview

Stocks Hitting 52-Week Highs

Share:
Related MDVN
In Wake Of Medivation Deal, Argus Thinks Pfizer's Existing Business Is Underrated
Here Are All The Big Biotech Mergers In 2016
Is Gilead Sciences A Bargain? (Seeking Alpha)
Related TEVA
Drug Price Hike Concerns Spill Over Into Other Pharma Stocks
Have You Heard About This Generic EpiPen Maker?
Mylan To Launch Its Own EpiPen Generic Rival At Half Price (Investor's Business Daily)

Medivation (NASDAQ: MDVN) shares touched a new 52-week high of $86.54 after the company and Astellas reported final results from the Phase 3 PREVAIL trial of Enzalutamide. Credit Suisse lifted the price target on Medivation from $80.00 to $95.00.

Teva Pharmaceutical Industries (NYSE: TEVA) shares reached a new 52-week high of $45.60 after the company reported the FDA approval of three-times-a-week COPAXONE 40mg/mL.

CBRE Group (NYSE: CBG) shares jumped 1.54% to touch a new 52-week high of $27.06. CBRE Group is expected release its Q4 financial results on February 5, 2014.

Jones Lang LaSalle (NYSE: JLL) shares surged 5.69% to reach a new 52-week high of $112.36 after the company reported stronger-than-expected Q4 results.

Posted-In: 52-Week HighsNews Intraday Update Markets Movers

 

Related Articles (CBG + JLL)

View Comments and Join the Discussion!